OptimizeRx Corp. (OPRX)

Q: What's priced into OptimizeRx Corp. (OPRX) stock?

The evidence labels valuation as expensive, while also showing OPRX as cheap versus peers, so the relative valuation picture is mixed. The priced-in tag is justified, with no fragility gates triggered, but the expectations gap is negative and confidence in the valuation model is medium.

Q: What does the OptimizeRx Corp. (OPRX) outlook hinge on?

The multi-year view hinges on whether customer investment and commercial momentum support management’s 2026 revenue guidance while margins and debt continue to improve. A guidance cut or further weakening in jobs could weigh on the business outlook, while continued strength among healthcare sector bellwethers could support the sector backdrop.

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$9.15+0.77%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge OptimizeRx Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	34.69M
EPS	—	0.43
FY 2026 · Annual
Revenue	$95M–$100M	96.23M
EPS	—	0.897
EBITDA	$21M–$25Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	106.6M
EPS	—	1.082

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve adjusted EBITDA guidance of $21M-$25M for FY26	The company targets adjusted EBITDA near $23 million.	Intact	adjusted EBITDA falls below $21 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve cash from operating activities from negative $0.47M in Q1 2026	It has announced share buybacks and seeks to improve cash flow.	Improving	cash from operations remains negative or worsens over next 4 quarters	Cash from operations: $8.611M FY2026-Q2; GAAP. Published target: cash from operations improves to positive territory. Target period is not explicitly aligned with this observation. Source published Aug 13, 20268,611,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue guidance of $109M-$114M for FY26	A primary condition in OptimizeRx Corp.'s published investment case. The stated target is >= $109 million and <= $114 million.	Intact	revenue falls below $109 million in FY26	Revenue: $20.504M FY2026-Q2; GAAP. Published target: >= $109 million and <= $114 million. Target period is not explicitly aligned with this observation. Source published Aug 13, 202620,504,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4c500ef2-e4b3-4009-9772-f8ec1b3459df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$1.09 → Unavailable · observed estimates

FY2027 revenue$0.11B

$0.11B → $0.11B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.09	$108,894,830	5 / 6
2026-07-25	$1.09	$108,894,830	5 / 6
2026-07-26	$1.09	$108,894,830	5 / 6
2026-07-27	Unavailable	$108,894,880	4 / 5
2026-07-28	$1.09	$108,894,830	5 / 6
2026-07-29	Unavailable	$108,894,880	4 / 5
2026-07-30	Unavailable	$108,894,880	4 / 5
2026-07-31	Unavailable	$108,894,880	4 / 5
2026-08-01	Unavailable	$108,894,880	4 / 5
2026-08-02	$1.09	$108,894,830	5 / 6
2026-08-03	$1.09	$108,894,830	5 / 6
2026-08-04	Unavailable	$108,894,880	4 / 5
2026-08-05	Unavailable	$108,894,880	4 / 5
2026-08-06	Unavailable	$108,894,880	4 / 5
2026-08-07	Unavailable	$108,894,880	4 / 5
2026-08-08	$1.09	$108,894,830	5 / 6
2026-08-09	$1.09	$108,894,830	5 / 6
2026-08-10	Unavailable	$108,894,880	4 / 5
2026-08-12	Unavailable	$108,894,880	4 / 5
2026-08-13	Unavailable	$108,894,880	4 / 5
2026-08-14	Unavailable	$108,894,880	4 / 5
2026-08-15	Unavailable	$108,894,880	4 / 5
2026-08-16	Unavailable	$108,894,880	4 / 5
2026-08-17	Unavailable	$108,894,880	4 / 5
2026-08-18	Unavailable	$108,894,880	4 / 5
2026-08-19	Unavailable	$108,894,880	4 / 5
2026-08-20	Unavailable	$107,636,333	3 / 5
2026-08-21	Unavailable	$107,636,333	3 / 5
2026-08-22	Unavailable	$107,636,333	3 / 5
2026-08-23	Unavailable	$107,636,333	3 / 5
2026-08-24	Unavailable	$107,636,333	3 / 5
2026-08-25	Unavailable	$107,636,333	3 / 5
2026-08-26	Unavailable	$107,636,333	3 / 5
2026-08-27	Unavailable	$107,636,333	3 / 5
2026-08-28	Unavailable	$107,636,333	3 / 5
2026-08-29	Unavailable	$107,636,333	3 / 5
2026-08-30	Unavailable	$107,636,333	3 / 5
2026-08-31	Unavailable	$107,636,333	3 / 5
2026-09-01	Unavailable	$107,636,333	3 / 5
2026-09-02	Unavailable	$107,636,333	3 / 5
2026-09-03	Unavailable	$107,636,333	3 / 5
2026-09-04	Unavailable	$107,636,333	3 / 5
2026-09-05	Unavailable	$107,636,333	3 / 5
2026-09-06	Unavailable	$107,636,333	3 / 5
2026-09-07	Unavailable	$107,636,333	3 / 5
2026-09-08	Unavailable	$107,636,333	3 / 5
2026-09-09	Unavailable	$107,636,333	3 / 5
2026-09-10	Unavailable	$107,636,333	3 / 5
2026-09-11	Unavailable	$107,636,333	3 / 5
2026-09-12	Unavailable	$107,636,333	3 / 5
2026-09-13	Unavailable	$107,636,333	3 / 5
2026-09-14	Unavailable	$107,636,333	3 / 5
2026-09-15	Unavailable	$107,636,333	3 / 5
2026-09-16	Unavailable	$107,636,333	3 / 5
2026-09-17	Unavailable	$107,636,333	3 / 5
2026-09-18	Unavailable	$107,636,333	3 / 5
2026-09-19	Unavailable	$107,636,333	3 / 5
2026-09-20	Unavailable	$107,636,333	3 / 5
2026-09-21	Unavailable	$107,636,333	3 / 5
2026-09-22	Unavailable	$107,636,333	3 / 5
2026-09-23	Unavailable	$107,636,333	3 / 5
2026-09-24	Unavailable	$107,636,333	3 / 5
2026-09-25	Unavailable	$107,636,333	3 / 5
2026-09-26	Unavailable	$107,636,333	3 / 5
2026-09-27	Unavailable	$107,636,333	3 / 5
2026-09-28	Unavailable	$107,636,333	3 / 5
2026-09-29	Unavailable	$107,636,333	3 / 5
2026-09-30	Unavailable	$107,636,333	3 / 5
2026-10-01	Unavailable	$106,554,833	3 / 5
2026-10-02	Unavailable	$106,554,833	3 / 5
2026-10-03	Unavailable	$106,554,833	4 / 5
2026-10-04	Unavailable	$106,595,500	4 / 5
2026-10-05	Unavailable	$106,595,500	4 / 5
2026-10-06	Unavailable	$106,595,500	4 / 5
2026-10-07	Unavailable	$106,595,500	4 / 5
2026-10-08	Unavailable	$106,595,500	4 / 5
2026-10-09	Unavailable	$106,595,500	4 / 5
2026-10-10	Unavailable	$106,595,500	4 / 5
2026-10-11	Unavailable	$106,595,500	4 / 5
2026-10-12	Unavailable	$106,595,500	4 / 5
2026-10-13	Unavailable	$106,595,500	4 / 5
2026-10-14	Unavailable	$106,595,500	4 / 5
2026-10-15	Unavailable	$106,595,500	4 / 5
2026-10-16	Unavailable	$106,595,500	4 / 5
2026-10-17	Unavailable	$106,595,500	4 / 5
2026-10-18	Unavailable	$106,595,500	4 / 5
2026-10-19	Unavailable	$106,595,500	4 / 5
2026-10-20	Unavailable	$106,595,500	4 / 5
2026-10-21	Unavailable	$106,595,500	4 / 5
2026-10-22	Unavailable	$106,595,500	4 / 5
2026-10-23	Unavailable	$106,595,500	4 / 5
2026-10-24	Unavailable	$106,595,500	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	6	0
2026-08-01	6	0
2026-09-01	6	0
2026-10-01	6	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve adjusted EBITDA guidance of $21M-$25M for FY26Direct metric needs a verified mapping
Improve cash from operating activities from negative $0.47M in Q1 2026Cash from operations: $8.611M
Achieve revenue guidance of $109M-$114M for FY26Revenue: $20.504M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-79.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

OptimizeRx Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

OPRX is a high-risk growth business with strong recent performance but ongoing losses. Its long-term thesis is intact, though the latest signal has shifted from mildly favorable to mixed.

What's priced into OptimizeRx Corp.

The evidence labels valuation as expensive, while also showing OPRX as cheap versus peers, so the relative valuation picture is mixed. The priced-in tag is justified, with no fragility gates triggered, but the expectations gap is negative and confidence in the valuation model is medium.

What the fundamentals likely do

Near term, revenue and adjusted EBITDA are under pressure: second-quarter revenue fell year over year, and adjusted EBITDA declined. Management reiterated its 2026 guidance and has paid down debt, but the revenue goal remains a meaningful execution test; the latest earnings event was positive, while a CFO transition adds a management change to watch.

What OptimizeRx Corp. hinges on

The multi-year view hinges on whether customer investment and commercial momentum support management’s 2026 revenue guidance while margins and debt continue to improve. A guidance cut or further weakening in jobs could weigh on the business outlook, while continued strength among healthcare sector bellwethers could support the sector backdrop.

Bottom line

Over the next 1 to 3 years, OPRX combines strong recent performance and debt reduction with losses, high risk, and near-term revenue pressure. The long-term thesis depends on management delivering its guidance and sustaining commercial momentum. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	34.69M
EPS	—	0.43
FY 2026 · Annual
Revenue	$95M–$100M	96.23M
EPS	—	0.897
EBITDA	$21M–$25Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	106.6M
EPS	—	1.082

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$1.09 → Unavailable · observed estimates

FY2027 revenue$0.11B

$0.11B → $0.11B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.09	$108,894,830	5 / 6
2026-07-25	$1.09	$108,894,830	5 / 6
2026-07-26	$1.09	$108,894,830	5 / 6
2026-07-27	Unavailable	$108,894,880	4 / 5
2026-07-28	$1.09	$108,894,830	5 / 6
2026-07-29	Unavailable	$108,894,880	4 / 5
2026-07-30	Unavailable	$108,894,880	4 / 5
2026-07-31	Unavailable	$108,894,880	4 / 5
2026-08-01	Unavailable	$108,894,880	4 / 5
2026-08-02	$1.09	$108,894,830	5 / 6
2026-08-03	$1.09	$108,894,830	5 / 6
2026-08-04	Unavailable	$108,894,880	4 / 5
2026-08-05	Unavailable	$108,894,880	4 / 5
2026-08-06	Unavailable	$108,894,880	4 / 5
2026-08-07	Unavailable	$108,894,880	4 / 5
2026-08-08	$1.09	$108,894,830	5 / 6
2026-08-09	$1.09	$108,894,830	5 / 6
2026-08-10	Unavailable	$108,894,880	4 / 5
2026-08-12	Unavailable	$108,894,880	4 / 5
2026-08-13	Unavailable	$108,894,880	4 / 5
2026-08-14	Unavailable	$108,894,880	4 / 5
2026-08-15	Unavailable	$108,894,880	4 / 5
2026-08-16	Unavailable	$108,894,880	4 / 5
2026-08-17	Unavailable	$108,894,880	4 / 5
2026-08-18	Unavailable	$108,894,880	4 / 5
2026-08-19	Unavailable	$108,894,880	4 / 5
2026-08-20	Unavailable	$107,636,333	3 / 5
2026-08-21	Unavailable	$107,636,333	3 / 5
2026-08-22	Unavailable	$107,636,333	3 / 5
2026-08-23	Unavailable	$107,636,333	3 / 5
2026-08-24	Unavailable	$107,636,333	3 / 5
2026-08-25	Unavailable	$107,636,333	3 / 5
2026-08-26	Unavailable	$107,636,333	3 / 5
2026-08-27	Unavailable	$107,636,333	3 / 5
2026-08-28	Unavailable	$107,636,333	3 / 5
2026-08-29	Unavailable	$107,636,333	3 / 5
2026-08-30	Unavailable	$107,636,333	3 / 5
2026-08-31	Unavailable	$107,636,333	3 / 5
2026-09-01	Unavailable	$107,636,333	3 / 5
2026-09-02	Unavailable	$107,636,333	3 / 5
2026-09-03	Unavailable	$107,636,333	3 / 5
2026-09-04	Unavailable	$107,636,333	3 / 5
2026-09-05	Unavailable	$107,636,333	3 / 5
2026-09-06	Unavailable	$107,636,333	3 / 5
2026-09-07	Unavailable	$107,636,333	3 / 5
2026-09-08	Unavailable	$107,636,333	3 / 5
2026-09-09	Unavailable	$107,636,333	3 / 5
2026-09-10	Unavailable	$107,636,333	3 / 5
2026-09-11	Unavailable	$107,636,333	3 / 5
2026-09-12	Unavailable	$107,636,333	3 / 5
2026-09-13	Unavailable	$107,636,333	3 / 5
2026-09-14	Unavailable	$107,636,333	3 / 5
2026-09-15	Unavailable	$107,636,333	3 / 5
2026-09-16	Unavailable	$107,636,333	3 / 5
2026-09-17	Unavailable	$107,636,333	3 / 5
2026-09-18	Unavailable	$107,636,333	3 / 5
2026-09-19	Unavailable	$107,636,333	3 / 5
2026-09-20	Unavailable	$107,636,333	3 / 5
2026-09-21	Unavailable	$107,636,333	3 / 5
2026-09-22	Unavailable	$107,636,333	3 / 5
2026-09-23	Unavailable	$107,636,333	3 / 5
2026-09-24	Unavailable	$107,636,333	3 / 5
2026-09-25	Unavailable	$107,636,333	3 / 5
2026-09-26	Unavailable	$107,636,333	3 / 5
2026-09-27	Unavailable	$107,636,333	3 / 5
2026-09-28	Unavailable	$107,636,333	3 / 5
2026-09-29	Unavailable	$107,636,333	3 / 5
2026-09-30	Unavailable	$107,636,333	3 / 5
2026-10-01	Unavailable	$106,554,833	3 / 5
2026-10-02	Unavailable	$106,554,833	3 / 5
2026-10-03	Unavailable	$106,554,833	4 / 5
2026-10-04	Unavailable	$106,595,500	4 / 5
2026-10-05	Unavailable	$106,595,500	4 / 5
2026-10-06	Unavailable	$106,595,500	4 / 5
2026-10-07	Unavailable	$106,595,500	4 / 5
2026-10-08	Unavailable	$106,595,500	4 / 5
2026-10-09	Unavailable	$106,595,500	4 / 5
2026-10-10	Unavailable	$106,595,500	4 / 5
2026-10-11	Unavailable	$106,595,500	4 / 5
2026-10-12	Unavailable	$106,595,500	4 / 5
2026-10-13	Unavailable	$106,595,500	4 / 5
2026-10-14	Unavailable	$106,595,500	4 / 5
2026-10-15	Unavailable	$106,595,500	4 / 5
2026-10-16	Unavailable	$106,595,500	4 / 5
2026-10-17	Unavailable	$106,595,500	4 / 5
2026-10-18	Unavailable	$106,595,500	4 / 5
2026-10-19	Unavailable	$106,595,500	4 / 5
2026-10-20	Unavailable	$106,595,500	4 / 5
2026-10-21	Unavailable	$106,595,500	4 / 5
2026-10-22	Unavailable	$106,595,500	4 / 5
2026-10-23	Unavailable	$106,595,500	4 / 5
2026-10-24	Unavailable	$106,595,500	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings